Jaffer A. Ajani, Ken Kato, Futang Yang, Qingyu Wang, Lin Shen. "A randomized, double-blinded, international phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJ cancer.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.2_suppl.tps467